What is Tirzepatide 2.5mg?

A 39-amino-acid synthetic peptide conjugated to a C20 fatty-diacid moiety and characterised as a dual GIP/GLP-1 receptor agonist. Avion supplies this Prefilled research pen strictly as a laboratory, analytical and non-clinical research product.

What technical identity information is available for Tirzepatide?

The page lists molecular and registry data where a reliable public record exists. Where public identity is ambiguous or the product is a blend, Avion explicitly defers to the applicable batch COA rather than publishing a fabricated single-molecule specification.

How is Tirzepatide 2.5mg quality documented?

Avion uses independent third-party purity and quantity verification. Exact methods and measured values are batch-specific and are taken from the applicable COA; a >99% statement is only used where that batch documentation confirms it.

Where can I read research literature for Tirzepatide?

Use the external PubChem and PubMed links in the Technical Identity section, together with Avion Research Hub and Research Library content where available.

How should Tirzepatide 2.5mg be stored?

Store refrigerated at 2°C–8°C, protected from light, in accordance with the product label and batch documentation. Do not freeze unless the applicable documentation states otherwise.

Where can I find batch documentation?

No public current batch record is connected to this page. Contact Avion BioLabs for product-specific documentation where available.

Is this product intended for human consumption?

No. It is supplied strictly for laboratory, analytical and non-clinical research and is not a medicine or consumer product.

Tirzepatide 2.5mg Prefilled Research Pen UK

Name: Tirzepatide 2.5mg
Brand: Avion BioLabs
SKU: AB-TZ25-PEN
Price: 109.99 GBP
Availability: InStock

Compound overview

Product-specific research context

What Tirzepatide is and why it appears in research literature

A 39-amino-acid synthetic peptide conjugated to a C20 fatty-diacid moiety and characterised as a dual GIP/GLP-1 receptor agonist. GIP receptor pharmacology; GLP-1 receptor pharmacology; Receptor occupancy, signalling bias and metabolic pathway models. This 2.5mg presentation includes one prefilled research pen and 5 × 32G needles, with the compound and strength clearly identified. This page separates published compound identity from batch-specific analytical claims so that formulae, purity and supplied form are not inferred where the source record does not support them.

Research Hub

Read the supporting context

All articles

Compound Research

Tirzepatide 2.5mg
Technical & Research Record

What Tirzepatide is and why it appears in research literature

Read the supporting context

Tirzepatide: What Is It Being Studied For?

Tirzepatide Research: GIP and GLP-1 Pathway Context

Tirzepatide vs Retatrutide: How the Research Questions Differ

Retatrutide vs Tirzepatide: Triple vs Dual Receptor Research Compared

Tirzepatide
2.5mg

Tirzepatide 2.5mg specifications

Research pathways associated with Tirzepatide

How Tirzepatide is investigated

GIP receptor pharmacology

GLP-1 receptor pharmacology

Receptor occupancy, signalling bias and metabolic pathway models

Testing, purity and quantity evidence

Format and contents

Protect the material and its records

Database records and primary literature

Tirzepatide batch evidence

Tirzepatide 2.5mg information

What Tirzepatide is and why it appears in research literature

Tirzepatide: What Is It Being Studied For?

Tirzepatide Research: GIP and GLP-1 Pathway Context

Tirzepatide vs Retatrutide: How the Research Questions Differ

Retatrutide vs Tirzepatide: Triple vs Dual Receptor Research Compared

Tirzepatide 5mg

Tirzepatide 60mg

Tirzepatide2.5mg

Research pathways associated with Tirzepatide

GIP receptor pharmacology

GLP-1 receptor pharmacology

Receptor occupancy, signalling bias and metabolic pathway models

Testing, purity and quantity evidence

Format and contents

Protect the material and its records

Database records and primary literature

Tirzepatide
2.5mg